NCT05741359View on ClinicalTrials.gov

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

January 20, 2024

Study Completion Date

March 15, 2024

Conditions
Non-hodgkin Lymphoma,B Cell
Interventions
DRUG

CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

Trial Locations (3)

Unknown

RECRUITING

Wuhan Union Hospital, Wuhan

RECRUITING

Tianjin Institute of Hematology, Tianjin

RECRUITING

The First Affiliated Hospital of Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

Zhejiang University

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT05741359 - The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter